We have two partnership agreements with Genentech Inc., a member of the Roche group: the first aiming to develop an antibody targeting misfolded amyloid beta (Abeta) and the second focusing on anti-Tau antibodies for use as immunotherapeutics and diagnostics. AC Immune will regain the rights to both antibodies, as announced on January 22nd, 2024, following the termination of these agreements (effective April 19th, 2024).
In 2006, AC Immune signed an exclusive out-licensing agreement for its anti-Abeta antibody program with Genentech, under which Genentech develops crenezumab for the treatment and prevention of Alzheimer’s disease. Under the agreement with Genentech, we may become eligible to receive payments potentially greater than USD 340 (CHF 333) million, plus royalties. The Phase 2 development of crenezumab continues in a preventive trial of cognitively healthy individuals in Colombia with a risk of developing Alzheimer’s disease, the Alzheimer Prevention Initiative Autosomal Dominant Alzheimer’s Disease (API ADAD) Colombia Trial.
In June 2012, AC Immune entered into a second exclusive worldwide license agreement and research collaboration with Genentech for the research, development and commercialization of anti-Tau antibodies for the potential treatment and diagnosis of Alzheimer’s disease and other neurodegenerative diseases. The value of this exclusive, worldwide alliance is potentially greater than CHF 400 million, plus royalties.